Scarica l'app Stockscreener
5.33
3.09%
-0.17
Dopo l'orario di chiusura:
5.31
-0.02
-0.38%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALGS Giù?
Forum
Previsione
Precedente Chiudi:
$5.50
Aprire:
$5.38
Volume 24 ore:
46,061
Relative Volume:
0.30
Capitalizzazione di mercato:
$33.28M
Reddito:
$4.71M
Utile/perdita netta:
$-90.32M
Rapporto P/E:
-0.6124
EPS:
-8.7032
Flusso di cassa netto:
$-85.19M
1 W Prestazione:
-14.31%
1M Prestazione:
-30.33%
6M Prestazione:
-24.93%
1 anno Prestazione:
-50.23%
Intervallo 1D:
$5.21
$5.48
Intervallo di 1 settimana:
$5.21
$6.3396
Portata 52W:
$3.98
$13.69
Aligos Therapeutics Inc Stock (ALGS) Company Profile
Nome
Aligos Therapeutics Inc
Settore
Industria
Telefono
(800) 466-6059
Indirizzo
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
Compare ALGS vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALGS
Aligos Therapeutics Inc
|
5.33 | 34.35M | 4.71M | -90.32M | -85.19M | -8.7032 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-19 | Ripresa | Jefferies | Buy |
| 2025-08-18 | Ripresa | H.C. Wainwright | Buy |
| 2024-08-19 | Iniziato | H.C. Wainwright | Buy |
| 2023-01-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-01-06 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-03-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-01-07 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-01-06 | Downgrade | Jefferies | Buy → Hold |
| 2021-09-09 | Iniziato | SVB Leerink | Outperform |
| 2021-05-17 | Ripresa | Piper Sandler | Overweight |
| 2020-11-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-11-10 | Iniziato | JP Morgan | Overweight |
| 2020-11-10 | Iniziato | Jefferies | Buy |
| 2020-11-10 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Aligos Therapeutics Inc Borsa (ALGS) Ultime notizie
Aligos Therapeutics at Cantor Fitzgerald conference: hbv pipeline in focus By Investing.com - Investing.com India
ALGS Stock Rallies 16% After-Hours On $25M Cash Boost From China Hepatitis B Drug Deal - Stocktwits
Liquidity Mapping Around (ALGS) Price Events - Stock Traders Daily
Aligos Therapeutics to Present at the Cantor Global Healthcare Conference - Investing News Network
Why is Aligos Therapeutics stock rallying 7% today? - Investing.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - benzinga.com
Why is Aligos Therapeutics stock rallying 7% today? By Investing.com - Investing.com India
Aligos Therapeutics Shares Rise 7.6% Premarket Following Recent Company Updates - Yahoo Finance
Stock Market News - Investing.com South Africa
Aligos Therapeutics (ALGS) Stock Forum and Discussion - Moomoo
Aligos Hepatitis B Trial Completion: What Phase 1 Liver Data Mean for ALGS Investors - TipRanks
Aligos Therapeutics Company Profile & Introduction - Moomoo
Aligos Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Why (ALGS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Industry Analysts Just Upgraded Their Aligos Therapeutics, Inc. (NASDAQ:ALGS) Revenue Forecasts By 68% - Moomoo
Aligos Therapeutics (ALGS) Slips 1.55% to $6.67 as Biotech Stock Holds Above Key SupportSector Leader Stocks - vinanet.vn
Aligos Therapeutics, Inc. (ALGS) Stock Price, News, Quote & History - Yahoo Finance
Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China - Investing News Network
Aligos Therapeutics Announces First Participant Dosed In The Phase 1 Study Of Its Potentially Best-In-Class Antisense Oligonucleotide Alg-170675 By Its Partner Amoytop In China - TradingView
Aligos begins phase 1 trial of hepatitis B treatment in China - Investing.com South Africa
Aligos Begins Testing a Chronic Hepatitis B Candidate in China - Stock Titan
Industry Analysts Just Made A Stunning Upgrade To Their Aligos Therapeutics, Inc. (NASDAQ:ALGS) Revenue Forecasts - simplywall.st
H.C. Wainwright reiterates Aligos stock rating on HBV progress By Investing.com - Investing.com UK
H.C. Wainwright reiterates Aligos stock rating on HBV progress - Investing.com
Lake Street Keeps Their Buy Rating on Aligos Therapeutics (ALGS) - The Globe and Mail
Aligos Therapeutics Inc (NASDAQ:ALGS) - intelligentinvestor.com.au
ALGS Q2 2026 Earnings: Narrowed Loss Beats Estimates by 87% as Stock Advances 1.45Healthcare Earnings Report - Vinanet
Cantor Fitzgerald Maintains Aligos Therapeutics(ALGS.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Aligos earnings beat by $1.01, revenue topped estimates - Investing.com Canada
Form 8K Aligos Therapeutics Inc For: 6 August By Investing.com - Investing.com Nigeria
Form 8K Aligos Therapeutics Inc For: 6 August - Investing.com India
Aligos Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Aligos Therapeutics Reports $1.5 Million Q2 Net Loss and Pipeline Progress | ALGS Stock News - Quiver Quantitative
Aligos Therapeutics 2Q 2026: Revenue $—, Net income $(1.50)M, EPS $(0.14) — 10-Q Summary - TradingView
ALGS: $27.8M licensing revenue drove a smaller Q2 loss; cash runway into Q4 2026, funding needed - TradingView
Aligos Therapeutics (Nasdaq: ALGS) logs Q2 loss but lands $27.8M HBV license revenue - Stock Titan
Aligos Therapeutics reports Q2 2026: $27.8M licensing revenue, $1.5M net loss, $30.4M cash - TradingView
ALGS: Pipeline advances and licensing deals strengthen financials and outlook for HBV therapies - TradingView
ALIGOS THERAPEUTICS Q2 NET INCOME USD -1.504 MILLION - Moomoo
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results - Yahoo Finance
8-K: Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Resultsmoomoo - Moomoo
ALGS Q2'26 Earnings: EPS estimate is (1.09) USD - TradingView
Aligos Therapeutics, Inc. expected to post a loss of $1.07 a shareEarnings Preview - TradingView
Aligos Therapeutics (ALGS) Rises 0.87% to $4.64, Holds Above SupportRSI Oversold Picks - vinanet.vn
Earnings Preview: ALGS to Report Financial Results Pre-market on August 06 - moomoo.com
Aligos Therapeutics Inc expected to post a loss of $1.07 a shareEarnings Preview - TradingView
Aligos Therapeutics (ALGS) Edges Higher as Biotech Sector Shows Mixed SignalsMACD Signal Stocks - vinanet.vn
Aligos Therapeutics Inc (ALGS) Cash Flow - TradingKey
Aligos Therapeutics Inc (ALGS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ALGS|Aligos Therapeutics Inc|Price:7.600|Chg%:+2.010 - TradingKey
ALGS|Aligos Therapeutics Inc|Price:4.075|Chg%:-0.005 - TradingKey
Aligos Therapeutics Inc Azioni (ALGS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):